Case Report
Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still’s Disease

Yoshika Tsuji, Nozomi Iwanaga, Anna Adachi, Kinuyo Tsunozaki, Yasumori Izumi, Yuji Moriwaki, Kazuhiro Kurohama, Masahiro Ito, Atsushi Kawakami, and Kiyoshi Migita

1Department of General Internal Medicine and Rheumatology, Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
2Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
3Department of Hematology, Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
4Department of Pathology, Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
5Department of Rheumatology, Nagasaki University Hospital, Nagasaki 852-8121, Japan

Correspondence should be addressed to Kiyoshi Migita; migita@nagasaki-mc.com

Received 4 November 2015; Revised 4 December 2015; Accepted 8 December 2015

1. Introduction
Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. AOSD is characterized by spiking fevers with an evanescent rash, arthritis, and multiorgan involvement [1]. According to the clinical presentation of this disease at diagnosis, two AOSD phenotypes may be distinguished: (i) a highly symptomatic, systemic, and feverish phenotype, which evolves into a systemic (mono- or poly-cyclic) pattern; (ii) a more indolent phenotype with arthritis, which evolves into a chronic articular pattern [2]. Steroid- or disease modified antirheumatic drugs- (DMARDs-) refractory AOSD cases currently benefit from recent insights into autoinflammatory disorders. Anticytokine treatment appears to be an efficient, well-tolerated, steroid-sparing treatment in systemic patterns [3]. Tocilizumab appears to be efficient in AOSD with active arthritis and systemic symptoms [4, 5]. Macrophage-activation syndrome (MAS) is a disorder characterized by hemophagocytosis and deregulation of T lymphocytes and macrophages and subsequent overproduction of cytokines [6]. MAS can occur in rheumatic disease and is frequently observed in patients with AOSD [7]. Despite major advances in the understanding of MAS, further studies are required to determine the therapeutic approach to regulate the “cytokine storm.” Cytokine-directed therapies have the potential to target the effector molecules in MAS [8] and MAS complicating AOSD were successfully treated by these therapies [9, 10]. However, manifestations of MAS during biologics therapy have been also reported [11]. We report a case of MAS that was complicated by AOSD and was successfully treated with intravenous cyclophosphamide (IV-CY).

2. Case Report
A 64-year-old Japanese woman was admitted to our hospital because of fever, polymyalgia, and sore throat. She had been well until approximately 2 weeks earlier, when her
sore throat developed. One week later, she developed a spiking fever and an evanescent skin rash on the upper limbs and trunk, followed by polyarthralgia. Upon examination, inflammatory arthritis of the shoulder and elbow joints and muscle tenderness of the upper extremities coinciding with the erythematous skin rash on her trunk and spiking fever (>39°C) were evident. Initial blood data on admission were as follows (Table 1): leukocytes, 26,000/μL (neutrophils, 90.0%); hemoglobin, 12.0 g/dL; platelets, 29.3 × 10^4/μL; erythrocyte sedimentation rate, 71 mm/h; prothrombin time, INR 1.17; fibrinogen, 684.2 mg/dL; FDP, 13.2 μg/mL; C-reactive protein, 9.95 mg/dL; soluble interleukin-2 receptor, 1850 IU/L; and ferritin, 11740 ng/mL. Anti-nuclear antibodies and anti-CCP antibodies were negative. Serological tests for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) antigenemia showed negative results. Computed tomography (whole body) and fiberoptic analysis (upper and lower intestine) did not show the findings suggestive for malignancies. The diagnosis of AOSD was made according to Yamaguchi’s diagnostic criteria [12] based on the above-mentioned findings, including spiking fever, polyarthritis, salmon pink skin rash, leukocytosis, sore throat, and elevated serum transaminases. These findings met the classification for the systemic type of AOSD.

Steroid pulse therapy (methylprednisolone 1000 mg for 3 days) was started and followed by oral prednisolone (40 mg daily), which was combined with oral cyclosporin A (200 mg/day). After a transient improvement, a disease flare, which included spiking fever and further elevated levels of serum transaminases and ferritin, occurred on day 13 (Figure 1). On day 30, the white blood cells counts decreased (21000/μL to 9200/μL) and mild thrombocytopenia (36.7 × 10^4/μL to 13.7 × 10^4/μL) appeared within 10-day duration. Additionally, fibrinogen (687.5 mg/dL to 349.2 mg/dL) was decreased, and conversely triglyceride (186 mg/dL to 235 mg/dL) and FDP (7.4 μg/mL to 49.7 μg/mL) were increased. These subtle laboratory alternations also support the association of MAS.

Repeated serological analysis indicated no infection with parvovirus B19, hepatitis B virus (HBV), HCV, and EBV, and CMV antigenemia was not detected. Bone marrow aspiration showed phagocytosed blood cells and massive infiltrated CD68-positive monocytes (Figure 2). Based on the negative results for infectious agents, these observations indicated that the patient had hypercytokinemia and MAS associated with AOSD. She was treated with plasma exchange followed by steroid pulse therapy. Despite these intensified treatments, the spiking fever was sustained, and this was accompanied by sustained elevation of serum ferritin levels. Since the cytopenia was mild, we selected the low dose (500 mg) IV-CY treatment for MAS. She was treated with IV-CY (500 mg), and these combination therapies effectively reduced the disease activity of AOSD and MAS (Figure 1). Thereafter, the patient has been successfully maintained on IV-CY every one-month interval (total of six times) in combination with a maintenance dose of oral prednisolone and oral cyclosporin A.

### Table 1: Laboratory findings on admission.

| Peripheral blood |   |
|------------------|--|
| Red blood cells   | 382 × 10^6/μL |
| Hemoglobin        | 12.0 g/dL     |
| Hematocrit        | 33.9%         |
| White blood cells | 26,000/μL     |
| Neutrophil        | 90.0%         |
| Monocyte          | 3.0%          |
| Lymphocyte        | 5.0%          |
| Platelet          | 29.3 × 10^4/μL|

| Blood chemistry   |   |
|-------------------|--|
| Total protein     | 5.7 g/dL |
| Total bilirubin   | 1.0 mg/dL |
| AST               | 34 IU/L (7–33) |
| ALT               | 22 IU/L (5–30) |
| Lactate dehydrogenase | 1095 IU/L (119–229) |
| Alkaline phosphatase | 611 IU/L (80–250) |
| Gamma-glutamyl transpeptidase | 257 IU/L (5–53) |
| Creatinine kinase | 14 IU/L (60–160) |
| Total cholesterol | 186 mg/dL |
| Triglyceride      | 225 mg/dL |
| Blood urea nitrogen | 13.6 mg/dL |
| Creatinine        | 0.4 mg/dL |
| Alb               | 2.1 g/dL |
| Na                | 131 mEq/L |
| K                 | 4.1 mEq/L |
| Cl                | 91 mEq/L |

| Serological tests |   |
|-------------------|--|
| C-reactive protein | 9.95 mg/dL (<30) |
| Erythrocyte sedimentation rate | 71.0 mm/hr |
| Ferritin           | 11740 mg/mL (<170) |
| C3                | 142 mg/dL (86–160) |
| C4                | 26 mg/dL (17–45) |
| ANA               | (<40) |
| Anti-CCP Ab       | <0.6 U/mL (<4.5) |
| MPO-ANCA          | <1.0 U/mL |
| RR3-ANCA          | <1.0 U/mL |
| IgG               | 1340 mg/dL (900–2000) |
| IgA               | 108 mg/dL |
| sIL-2R            | 338 mg/dL |
| Coagulation       |   |
| PT time (INR)     | 67.8% (1.9) |
| Fibrinogen        | 684.2 mg/dL |
| FDP               | 13.2 μg/mL |

| Microbiological test |   |
|----------------------|--|
| HCV-Ab               | (—) |
| HBsAg                | (—) |
| CMV antigenemia      | (—) |
| EBV-EBNA             | ×40 |
| EBV-VCA IgM          | ×10 |
| EBV-VCA IgG          | ×160 |
| Blood culture        | (—) |
| β-D-Glucan           | <3.4 pg/mL |
| Urinalysis           | Normal |

ANA: anti-nuclear antibody; ANCA: antineutrophil cytoplasmic antibody; CMV: cytomegalovirus; EBV EBNA: Epstein-Barr virus, nuclear antigen; EBV-VCA: Epstein-Barr virus viral-capsid antigen; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; MMP-3: matrix metalloproteinase-3; MPO: myeloperoxidase; RF: rheumatoid factor; RR3: proteinase 3.
Fever
Arthralgia

**Figure 1:** Clinical course. CyA: cyclosporine A; IV-CY: intravenous cyclophosphamide; mPSL: methylprednisolone; PE: plasma exchange.

**Figure 2:** (a) The phagocytic reticular cells (arrows). The phagocytosis of mature neutrophils by phagocytic reticular cells is present. Hematoxylin and eosin (HE) staining. (b) Immunohistochemistry showing monocyte infiltrations in bone marrow. The CD68+ cells increased and were diffusely distributed in stroma of bone marrow. Immunohistochemical staining using antibodies against CD68.

### 3. Discussion

AOSD often poses a diagnostic and therapeutic challenge, and clinical guidelines are lacking [13]. MAS is a disorder that is characterized by hemophagocytosis, inappropriate systemic proliferation of histiocytes throughout the reticuloendothelial system, dysregulation of T lymphocytes and macrophages, and subsequent overproduction of cytokines, such as interleukin-1, interleukin-6, and interferon-γ [14]. Among the rheumatic diseases, sJIA and AOSD are often associated with MAS, and one retrospective study indicated a high frequency (12%) of MAS in AOSD patients [15].

The application of new biological agents may provide clinicians with useful tools for the management of this complex systemic disorder [16]. In patients with systemic involvement with or without articular manifestation, biologics, such as interleukin-1 inhibitors and tocilizumab, have favorable effects in AOSD [17]. A growing body of evidence suggests the efficacy of biological agents against the treatment of steroid- or DMARDs-refractory AOSD [18]. However, these reports on AOSD did not include cases with hemophagocytic syndrome or MAS. Therefore, the efficacy of tocilizumab therapy for the active phase of AOSD with MAS is unclear. Physicians should be cautious of possible induction of biologics-related MAS [19, 20].

In a study by Wouters et al., of 18 trials of antirheumatic drugs used in 45 patients with disease refractory to NSAIDs and corticosteroids, only eight (44%) proved clinically efficacious [1]. Second-line treatments for patients with steroid-resistant refractory AOSD include cyclosporin A, leflunomide, and cyclophosphamide [21]. Studies have suggested that the use of immunosuppressive agents should be reserved for cases in which the combination of antirheumatic drugs
The efficacy of IV-CY could be drawn by the combination with tocilizumab, as demonstrated in our case, complete suppression of AOSD by IV-CY therapy in a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab [19], and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab [20].

Conflict of Interests

The authors declare that they have no competing interests.

References

[1] M. Gerfaud-Valentin, Y. Jamilloux, J. Iwaz, and P. Sève, “Adult-onset Still’s disease,” Autoimmunity Reviews, vol. 13, no. 7, pp. 708–722, 2014.
[2] B. Fautrel, E. Zing, J.-L. Golmard et al., “Proposal for a new set of classification criteria for adult-onset still disease,” Medicine, vol. 81, no. 3, pp. 194–200, 2002.
[3] I. A. Al-Homood, “Biologic treatments for adult-onset still's disease,” Rheumatology, vol. 53, no. 1, pp. 32–38, 2014.
[4] H. Nakahara, T. Mima, N. Yoshio-Hoshino, M. Matsushita, J. Hashimoto, and N. Nishimoto, “A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years,” Modern Rheumatology, vol. 19, no. 1, pp. 69–72, 2009.
[5] K. Matsumoto, T. Nagashima, S. Takatori et al., “Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab,” Clinical Rheumatology, vol. 28, no. 4, pp. 485–487, 2009.
[6] R. Dhote, J. Simon, T. Papo et al., “Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review,” Arthritis Care & Research, vol. 49, no. 5, pp. 633–639, 2003.
[7] L. K. Weaver and E. M. Behrens, “Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis,” Current Opinion in Rheumatology, vol. 26, no. 5, pp. 562–569, 2014.
[8] G. S. Schulert and A. A. Grom, “Macrophage activation syndrome and cytokine-directed therapies,” Best Practice and Research: Clinical Rheumatology, vol. 28, no. 2, pp. 277–292, 2014.
[9] N. K. Loh, M. Lucas, S. Fernandez, and D. Prentice, “Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra,” Internal Medicine Journal, vol. 42, no. 12, pp. 1358–1362, 2012.
[10] E. Savage, T. Wazir, M. Drake, R. Cuthbert, and G. Wright, “Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab,” Rheumatology, vol. 53, no. 7, Article ID keu019, pp. 1352–1353, 2014.
[11] P. Efthimiou and S. Georgy, “Pathogenesis and management of macrophage activation syndrome in adult Still disease,” Modern Rheumatology, vol. 24, no. 7, Article ID keu019, pp. 1352–1353, 2014.
[12] C. Sandhu, A. Chesney, E. Piliotis, R. Buckstein, and S. Koren, “Macrophage activation syndrome after etanercept treatment,” Journal of Rheumatology, vol. 34, no. 1, pp. 241–242, 2007.
[13] M. Yamaguchi, A. Ohta, T. Tsunematsu et al., “Preliminary criteria for classification of adult Still’s disease,” Journal of Rheumatology, vol. 19, no. 3, pp. 424–430, 1992.
[14] A. T. J. Maria, A. Le Quellec, C. Jorgensen, I. Touitou, S. Rivière, and P. Guilpain, “Adult onset still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions,” Autoimmunity Reviews, vol. 13, no. 11, pp. 1149–1159, 2014.
[15] G. N. Usmani, B. A. Woda, and P. E. Newburger, “Advances in understanding the pathogenesis of HLH,” British Journal of Haematology, vol. 161, no. 5, pp. 609–622, 2013.
[16] E. Minoia, S. Davi, A. Horne et al., “Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients,” Arthritis & Rheumatology, vol. 66, no. 11, pp. 3160–3169, 2014.
[17] J. Pouchot and J.-B. Arlet, “Biological treatment in adult-onset Still’s disease,” Best Practice and Research: Clinical Rheumatology, vol. 26, no. 4, pp. 477–487, 2012.
[18] F. Ortiz-Sanjuaín, R. Blanco, L. Bianco-Zarrabetia et al., “Efficacy of Anakinra in refractory adult-onset still's disease: multicenter study of 41 patients and literature review,” Medicine, vol. 94, no. 39, Article ID e554, 2015.
[19] F. Ortiz-Sanjuaín, R. Blanco, V. Calvo-Rio et al., “Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients,” Arthritis & Rheumatology, vol. 66, no. 6, pp. 1659–1665, 2014.
[20] C. Banse, O. Vittecoq, Y. Benhamou, M. Gauthier-Prieur, T. Lequerré, and H. Lévesque, “Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease,” Joint Bone Spine, vol. 80, no. 6, pp. 653–655, 2013.
[21] M. Kobayashi, Y. Takahashi, H. Yamashita, H. Kaneko, and A. Mimori, “Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome,” Modern Rheumatology, vol. 21, no. 1, pp. 92–96, 2011.
[22] P. Efthimiou and S. Georgy, “Pathogenesis and management of adult-onset Still’s disease,” Seminars in Arthritis and Rheumatism, vol. 36, no. 3, pp. 144–152, 2006.
[22] P. Efthimiou, P. K. Paik, and L. Bielory, “Diagnosis and management of adult onset Still’s disease,” *Annals of the Rheumatic Diseases*, vol. 65, no. 5, pp. 564–572, 2006.

[23] S. Kumakura and Y. Murakawa, “Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults,” *Arthritis and Rheumatology*, vol. 66, no. 8, pp. 2297–2307, 2014.

[24] J.-I. Henter, A. Horne, M. Aricó et al., “HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis,” *Pediatric Blood and Cancer*, vol. 48, no. 2, pp. 124–131, 2007.